soquelitinib
Small molecule
Evidence outlook · registrational
Peripheral T-Cell Lymphoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-11.
Also in development:Atopic Dermatitis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06561048 NCT06561048 · Peripheral T-Cell Lymphoma Registry: NCT06561048 | 3 | Progression-free survival (Up to 4 years post study treatment initiation) 2027-11 | In progress: results expected 1 Nov 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Atopic Dermatitis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Soquelitinib: this drug | Phase 2 | Small molecule | ITK | Weak signal | NCT06345404: Adverse events occurred in 41.7% of soquelitinib patients versus 50% of placebo patients; all were Grade 1 to 2 and led to no dose modifications or interruptions. In cohort 4, EASI 75, EASI 90 and IGA 0/1 were achieved by 75%, 25% and 33% of soquelitinib patients versus 20%, 0% and 0% on placebo. | |
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | Reliable signal | NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9% | |
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | Reliable signal | NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18% | |
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | Partial signal | NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol). | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Weak signal | NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4% | |
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5) | |
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | Reliable signal | NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26% NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6% | |
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | Reliable signal | NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12% | |
| Ruxolitinib (Opzelura) | Approved | Small molecule | JAK1/2 | Reliable signal | NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14) | |
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | Reliable signal | NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9% NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18% | |
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001 | |
| ADSTEM | Phase 3 | Cell therapy | autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Asivatrep | Phase 3 | Small molecule | TRPV1 | Reliable signal | NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001) | |
| Baricitinib (Olumiant) | Phase 3 | Small molecule | JAK, JAK1/2 | Reliable signal | NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8% | |
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | No reviewed efficacy summary in this indication | |
| LW402 | Phase 3 | Small molecule | JAK1 | Partial signal | No reviewed efficacy summary in this indication | |
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| Pumecitinib | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| QLM3003 | Phase 3 | Small molecule | JAK | Partial signal | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). | |
| Rezpegaldesleukin | Phase 3 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1819 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Soficitinib (ICP-332) | Phase 3 | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| SSGJ-611 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Reliable signal | NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher) | |
| Telikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| VC005 | Phase 3 | Small molecule | JAK1, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zemprocitinib | Phase 3 | Small molecule | JAK1 | Reliable signal | NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) | |
| Afimkibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Bosakitug | Phase 2 | Monoclonal antibody | TSLP | Weak signal | NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9) | |
| Camoteskimab | Phase 2 | Monoclonal antibody | IL-18 | Partial signal | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | Weak signal | Featured results are safety only in this race | |
| CMS-D001 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ENV-294 | Phase 2 | Small molecule | — | Weak signal | Featured results are safety only in this race | |
| EVO101 | Phase 2 | Small molecule | IRAK4 | Partial signal | NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed | |
| EVO301 | Phase 2 | Protein / enzyme therapeutic | IL-18 | Partial signal | NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01) | |
| FB825 | Phase 2 | Monoclonal antibody | CεmX domain of membrane-bound IgE (mIgE) | Weak signal | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Galvokimig | Phase 2 | Multispecific antibody | IL-13, IL-17A, IL-17F | Partial signal | Featured results are safety only in this race | |
| GHZ339 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| GIA632 | Phase 2 | Monoclonal antibody | IL-15 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 2 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| HY209gel | Phase 2 | Small molecule | GPCR19 / GPBAR1 (TGR5, bile acid receptor) | Partial signal | Featured results are safety only in this race | |
| IN-115314 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-95597528 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| JYP0061 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| KT-621 | Phase 2 | Small molecule | STAT6 | Weak signal | Featured results are safety only in this race | |
| Lepzacitinib | Phase 2 | Small molecule | JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| LNK01004 | Phase 2 | Small molecule | Pan-JAK | Partial signal | Featured results are safety only in this race | |
| LT-002-158 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 2 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Lutikizumab | Phase 2 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Modzatinib | Phase 2 | Small molecule | ITK and JAK3 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 52 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow soquelitinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (3)
June 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent